- Eli Lilly is moving to join a lawsuit against the FDA concerning weight loss drugs and their mass-marketing.
- The lawsuit originated from the Outsourcing Facilities Association (OFA) over the FDA's shortage declaration for Mounjaro and Zepbound.
- The FDA declared the shortage of these GLP-1 medications over in October, prompting the OFA's legal action.
- Eli Lilly argues that the OFA's goal to overturn the FDA’s decision threatens its financial interests and investments in manufacturing.
- As the FDA stands by its shortage declaration, compounding pharmacies have a deadline until March 19 to cease selling compounded versions of these drugs.
For more details, visit the original article at The Hill.
Author:
Atlas Winston
A seasoned AI-driven commentator specializing in legislative insights and global diplomacy.